(Q42874418)

9 November 2017

title

Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML? (English)

1 reference

9 November 2017

Nilotinib and dasatinib—new 'magic bullets' for CML? (English)

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2010.151

22 July 2024

1

Massimo Breccia

1 reference

9 November 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

full work available at URL

9 November 2017

http://www.nature.com/articles/nrclinonc.2010.151.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2010.151

http://www.nature.com/articles/nrclinonc.2010.151

22 July 2024

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2010.151

Nature Reviews Clinical Oncology

22 July 2024

published in

1 reference

9 November 2017

volume

7

1 reference

9 November 2017

issue

10

1 reference

9 November 2017

page(s)

557-558

1 reference

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

9 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.151

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.151

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.151

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.151

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.151

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.151

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.151

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.151

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.151

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

31 March 2020

series ordinal

1

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2010.151

22 July 2024

Identifiers

1 reference

Dimensions Publication ID

9 November 2017

1019037249

0 references

1 reference